ClinicalTrials.gg
RecruitingNCT05814237POS-ARI-ERUpdated Oct 29, 2026

POS-ARI-ER Observational Study of Acute Respiratory Infections

An observational study in Acute Respiratory Infection and Acute Respiratory Tract Infection, sponsored by European Clinical Research Alliance for Infectious Diseases (ECRAID). Recruiting at 27 sites in 10 countries. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by European Clinical Research Alliance for Infectious Diseases (ECRAID) · Observational

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Oct 29, 2026Site recruiting status changedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
11,750
Sex
All
01

Study summary

Acute respiratory infections (ARI) are one of the most frequent reasons for hospital admission and antibiotic use, and can be caused by a broad range of pathogens, including respiratory viruses with proven epidemic potential, e.g. influenza and coronaviruses. The POS-ARI-ER study will focus on describing the different routine diagnostic and therapeutic practices in the work-up and treatment of ARI, as well as clinical outcomes across the patient population. In addition, POS-ARI-ER aims to characterise both the adult and paediatric patient populations with ARI presenting to acute hospital settings in Europe, and the aetiology of ARI in these patients.

Read the detailed description

The POS-ARI-ER study is a perpetual, observational study (POS), designed to provide data for clinical characterisation of acute respiratory infections (ARIs) in adults presenting to hospital settings across Europe.

Establishing the etiological cause of ARI at the time of presentation is difficult with currently available diagnostic approaches. Improvements in diagnosis and strategies for use of targeted antibiotic and antiviral treatment strategies are needed to improve patient outcomes, and to reduce selection of antimicrobial resistance (AMR) and antiviral resistance. Recent advances in routine diagnostics in secondary care settings include molecular tests that can detect multiple pathogens simultaneously, and highly sensitive and specific point of care tests that can provide attending clinicians with rapid results. However, the implementation of these technologies into routine clinical practice within hospitals, and any impact on treatment decisions or patient outcomes, has not been widely evaluated.

The aim is to accurately characterise cases of ARIs presenting to acute hospital services, such as emergency departments and acute medical assessment units, in Europe.

Characterisation will focus on identifying the routine diagnostic methods (laboratory and point of care testing) and pharmacological interventions employed by different centres in patients presenting with ARI. Data will be collected using standardised report forms that capture clinical, laboratory and prescribing information. Participants will include those who require admission to hospital, as well as patients who are discharged the same day from the emergency department or acute medical assessment unit. In addition, a subset of participants will have single upper respiratory tract research sample (e.g. nose/throat swab) obtained at enrolment (within 24 hours), for pathogen detection by molecular methods.

Describing the variations in routine practice provides a foundation both to improve patient care through currently available approaches, as well as to inform areas of focus for development of new strategies.

02

Conditions studied

  • Acute Respiratory Infection
  • Acute Respiratory Tract Infection

Keywords

  • Infections
  • Communicable Diseases
03

In context

Infections

2,097 studies on the registry are indexed under Infections; 361 are open to participants now.

This study's planned enrollment of 11,750 is above the median of 300 across 688 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

European Clinical Research Alliance for Infectious Diseases (ECRAID) is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Group 1: Adults (≥ 18 years old) presenting to acute hospital services with suspected community-acquired acute respiratory tract infection Group 2: Infants, children and adolescents (\< 18 years old) presenting to acute hospital services with suspected community-acquired acute respiratory tract infection

Eligibility criteria

Inclusion Criteria:

Inclusion criterion for Group 1:

  • Age ≥ 18 years

Inclusion criterion for Group 2:

  • Age \< 18 years
  • Clinical suspicion of a new episode of acute respiratory tract infection, with onset in the last 10 days
  • Patient presents to an emergency room or secondary care setting
  • is provided by patient or their legal representative

Exclusion Criteria:

  • Patient has been transferred from another hospital
  • Patient admitted to hospital for >2 days at the time of enrolment
  • Patient has been previously enrolled in the POS-ARI-ER study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
11,750 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group 1

    Adults ≥ 18 years old

    Other: Data collection

  • Group 2

    Infants, children and adolescents \< 18 years old

    Other: Data collection

Interventions

  • OtherData collection

    Data collection from study participants to characterise diagnostic and therapeutic practices.

06

What researchers measure

Primary outcomes

  1. Proportion of adult patients undergoing ARI-relevant microbiology and virology investigations.

    Calculate the proportion of types of ARI-relevant microbiology and virology investigations performed.

    Time frame: Five years

  2. Proportion of adult patients receiving antibiotics, antivirals, antifungals and/or immunomodulators.

    Calculate the proportion of cases receiving antibiotics, antivirals, antifungals and/or immunomodulators.

    Time frame: Five years

  3. Clinical outcome of adults with community acquired ARI in acute hospital settings in Europe.

    Maximal score using the ordinal scale assessed at discharge, death or at 28 days after hospital admission: 6= death, 5= hospitalisation requiring extracorporeal membrane oxygenation (ECMO) and/or invasive mechanical ventilation, 4= hospitalisation requiring non invasive ventilation (NIV) and/or high flow nasal cannula (HFNC) oxygen therapy, 3= requiring supplemental oxygen (but not NIV/HFNC), 2= hospitalisation not requiring supplemental oxygen, 1= not hospitalised.

    Time frame: Last day in hospital, at death or 28 days after admission, whichever comes first.

  4. Length of hospital and/or ICU stay in adults with community acquired ARI in acute hospital settings in Europe.

    Number of days patient admitted to hospital or ICU.

    Time frame: Last day in hospital, at death or 28 days after admission, whichever comes first.

  5. Duration of NIV and IMV/ECMO in adults with community acquired ARI in acute hospital settings in Europe.

    Number of days patients receiving NIV and IMV/ECMO.

    Time frame: Last day in hospital, at death or 28 days after admission, whichever comes first.

  6. All cause mortality in adults with community acquired ARI in acute hospital settings in Europe.

    Total number of deaths for each ARI-related pathogen.

    Time frame: Last day in hospital, at death or 28 days after admission, whichever comes first.

Secondary outcomes

  1. Patient demographics of the adult patient population with ARI presenting to acute hospital settings in Europe.

    Evaluate demographics of patient population with ARI.

    Time frame: Five years

  2. Comorbidities in the adult patient population with ARI presenting to acute hospital settings in Europe.

    Evaluation of comorbidities in patient population with ARI.

    Time frame: Five years

  3. Presenting symptoms in the adult patient population with ARI presenting to acute hospital settings in Europe.

    Evaluation of presenting symptoms in the adult patient population with ARI.

    Time frame: Five years

  4. Physiological measurements in the adult patient population with ARI presenting to acute hospital settings in Europe.

    Evaluation of the physiological measurements in the adult patient population with ARI.

    Time frame: Five years

  5. Aetiology of ARI in adults presenting to acute hospital settings in Europe.

    Detection of putative pathogens in respiratory tract samples (research upper respiratory tract sample at presentation and ARI-relevant microbiology/virology results obtained through routine clinical care).

    Time frame: Five years

Other outcomes

  1. Association between clinical outcomes and diagnostic or treatment related variables, for different aetiologies of community acquired ARI in adults presenting to hospital across Europe.

    Maximal score on ordinal scale assessed at discharge, death or at 28 days after hospital admission: 6= death, 5= hospitalisation requiring extracorporeal membrane oxygenation (ECMO) and/or invasive mechanical ventilation, 4= hospitalisation requiring non invasive ventilation (NIV) and/or high flow nasal cannula (HFNC) oxygen therapy, 3= requiring supplemental oxygen (but not NIV/HFNC), 2= hospitalisation not requiring supplemental oxygen, 1= not hospitalised, stratified by pathogen.

    Time frame: Last day in hospital, at death or 28 days after admission, whichever comes first.

07

Study locations

11 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Feb 2027, 44 months after the start.

Of 262 non-industry observational studies under Infections, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 79. This study's planned 44 months is above that.

Counting every sponsor, half of 300 studies reached it within 35 months; a quarter within 18 and three quarters within 67.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Feb 2026 → Feb 2027 and completion Feb 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Apr 14, 2023
StartActual
Jun 20, 2023
Primary completionEst.
Feb 28, 2027was Feb 2026
CompletionEst.
Feb 28, 2027was Feb 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 3 sites removed. 14 sites changed recruiting status (14 now completed)
Show 14 sites
  • Erasme Hospital · Brussels, BelgiumRecruiting→Completed
  • University Hospital for Infectious Diseases, Zagreb · Zagreb, CroatiaRecruiting→Completed
  • CHU Grenoble · Grenoble, FranceRecruiting→Completed
  • CHU Lyon · Lyon, FranceRecruiting→Completed
  • CHU de Tours · Tours, FranceRecruiting→Completed
  • Azienda Ospedaliera Policlinico di Bari · Bari, ItalyRecruiting→Completed
  • Radboud University Medical Center · Nijmegen, NetherlandsRecruiting→Completed
  • Agrippa Ionescu Hospital, Carol Davila University of Medicine and Pharmacy Bucharest · Bucharest, RomaniaRecruiting→Completed
  • Infectious and Tropical Diseases Hospital "Dr. Victor Babes" · Bucharest, RomaniaRecruiting→Completed
  • NHS Lothian- Royal Infirmary of Edinburgh and St Johns Hospital · Edinburgh, United KingdomRecruiting→Completed
  • Gateshead Health NHS Foundation Trust · Gateshead, United KingdomRecruiting→Completed
  • Liverpool University Hospitals NHS Foundation Trust · Liverpool, United KingdomRecruiting→Completed
  • Royal Free London NHS Foundation Trust - Royal Free Hospital · London, United KingdomRecruiting→Completed
  • Sheffield Teaching Hospitals NSH Foundation Trust · Sheffield, United KingdomRecruiting→Completed
Show 7 added (2 Romania, 2 Spain, 1 Belgium, 1 Greece, 1 Netherlands)
  • Universitair Ziekenhuis Antwerpen · Antwerp, Belgium
  • General University Hospital of Patras · Pátrai, Greece
  • Amsterdam UMC · Amsterdam, Netherlands
  • Carol Davila University of Medicine and Pharmacy Bucharest · Bucharest, Romania
  • Cluj Napoca Infectious Disease Clinical Hospital · Cluj-Napoca, Romania
  • Hospital Universitario Vall d'Hebron · Barcelona, Spain
  • Hospital Universitario Virgen Macarena · Seville, Spain
Show 3 removed
  • General University Hospital of Patras · Patras, Greece
  • Cluj Napoca Infectious Disease Clinical Hospital · Cluj Napoca, Romania
  • Hospital Universitario Virgen Macarena · Sevilla, Spain
Oct 29, 2026
Primary completion
Feb 28, 2026→Feb 28, 2027
Oct 29, 2026
Study completion
Feb 28, 2026→Feb 28, 2027
Oct 29, 2026
Eligibility
Minimum age 18 Years→none; 5 criteria added
What changed in the criteria
  • AddedInclusion Criteria:
  • AddedInclusion criterion for Group 1:
  • AddedInclusion criterion for Group 2:
  • AddedAge < 18 years
  • AddedExclusion Criteria:
Oct 29, 2026
Interventions
Arms or interventions changed
Oct 29, 2026
Primary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameProportion of adult patients undergoing ARI-relevant microbiology and virology investigations.Four years → Five years
  • Time frameProportion of adult patients receiving antibiotics, antivirals, antifungals and/or immunomodulators.Four years → Five years
Oct 29, 2026
Secondary outcomes
5 time frame changed
What changed in the outcomes
  • Time framePatient demographics of the adult patient population with ARI presenting to acute hospital settings in Europe.Four years → Five years
  • Time frameComorbidities in the adult patient population with ARI presenting to acute hospital settings in Europe.Four years → Five years
  • Time framePresenting symptoms in the adult patient population with ARI presenting to acute hospital settings in Europe.Four years → Five years
  • Time framePhysiological measurements in the adult patient population with ARI presenting to acute hospital settings in Europe.Four years → Five years
  • Time frameAetiology of ARI in adults presenting to acute hospital settings in Europe.Four years → Five years
Oct 29, 2026
Contact
Study contact changed: p•••@ndm.ox.ac.uk · •••2979→p•••@ndm.ox.ac.uk · •••2974. See the current contact
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    7 sites added, 3 sites removed. 14 sites changed recruiting status (14 now completed)
    Show 14 sites
    • Erasme Hospital · Brussels, BelgiumRecruiting→Completed
    • University Hospital for Infectious Diseases, Zagreb · Zagreb, CroatiaRecruiting→Completed
    • CHU Grenoble · Grenoble, FranceRecruiting→Completed
    • CHU Lyon · Lyon, FranceRecruiting→Completed
    • CHU de Tours · Tours, FranceRecruiting→Completed
    • Azienda Ospedaliera Policlinico di Bari · Bari, ItalyRecruiting→Completed
    • Radboud University Medical Center · Nijmegen, NetherlandsRecruiting→Completed
    • Agrippa Ionescu Hospital, Carol Davila University of Medicine and Pharmacy Bucharest · Bucharest, RomaniaRecruiting→Completed
    • Infectious and Tropical Diseases Hospital "Dr. Victor Babes" · Bucharest, RomaniaRecruiting→Completed
    • NHS Lothian- Royal Infirmary of Edinburgh and St Johns Hospital · Edinburgh, United KingdomRecruiting→Completed
    • Gateshead Health NHS Foundation Trust · Gateshead, United KingdomRecruiting→Completed
    • Liverpool University Hospitals NHS Foundation Trust · Liverpool, United KingdomRecruiting→Completed
    • Royal Free London NHS Foundation Trust - Royal Free Hospital · London, United KingdomRecruiting→Completed
    • Sheffield Teaching Hospitals NSH Foundation Trust · Sheffield, United KingdomRecruiting→Completed
    Show 7 added (2 Romania, 2 Spain, 1 Belgium, 1 Greece, 1 Netherlands)
    • Universitair Ziekenhuis Antwerpen · Antwerp, Belgium
    • General University Hospital of Patras · Pátrai, Greece
    • Amsterdam UMC · Amsterdam, Netherlands
    • Carol Davila University of Medicine and Pharmacy Bucharest · Bucharest, Romania
    • Cluj Napoca Infectious Disease Clinical Hospital · Cluj-Napoca, Romania
    • Hospital Universitario Vall d'Hebron · Barcelona, Spain
    • Hospital Universitario Virgen Macarena · Seville, Spain
    Show 3 removed
    • General University Hospital of Patras · Patras, Greece
    • Cluj Napoca Infectious Disease Clinical Hospital · Cluj Napoca, Romania
    • Hospital Universitario Virgen Macarena · Sevilla, Spain
    Primary completion Feb 28, 2026→Feb 28, 2027
    Study completion Feb 28, 2026→Feb 28, 2027
    Eligibility Minimum age 18 Years→none; 5 criteria added
    What changed in the criteria
    • AddedInclusion Criteria:
    • AddedInclusion criterion for Group 1:
    • AddedInclusion criterion for Group 2:
    • AddedAge < 18 years
    • AddedExclusion Criteria:
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameProportion of adult patients undergoing ARI-relevant microbiology and virology investigations.Four years → Five years
    • Time frameProportion of adult patients receiving antibiotics, antivirals, antifungals and/or immunomodulators.Four years → Five years
    Secondary outcomes 5 time frame changed
    What changed in the outcomes
    • Time framePatient demographics of the adult patient population with ARI presenting to acute hospital settings in Europe.Four years → Five years
    • Time frameComorbidities in the adult patient population with ARI presenting to acute hospital settings in Europe.Four years → Five years
    • Time framePresenting symptoms in the adult patient population with ARI presenting to acute hospital settings in Europe.Four years → Five years
    • Time framePhysiological measurements in the adult patient population with ARI presenting to acute hospital settings in Europe.Four years → Five years
    • Time frameAetiology of ARI in adults presenting to acute hospital settings in Europe.Four years → Five years
    Interventions Arms or interventions changed
    Contact Study contact changed: p•••@ndm.ox.ac.uk · •••2979→p•••@ndm.ox.ac.uk · •••2974. See the current contact
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05814237
Lead sponsor
European Clinical Research Alliance for Infectious Diseases (ECRAID)
Responsible party
Sponsor
First posted
Apr 14, 2023
Start date
Jun 20, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Jake Dunning
Contact
pos-ari-er@ndm.ox.ac.uk
01865 612974

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion